Monitoring of 57Co-bleomycin delivery to brain metastases and their tumors of origin

D. Front, E. Even-Sapir, G. Iosilevsky, O. Israel, A. Frenkel, G. M. Kolodny, M. Feinsud

Research output: Contribution to journalArticlepeer-review

Abstract

The concentration of cobalt-57 (57Co)-labeled bleomycin delivered to three brain metastases and to their tumors of origin in the lungs was measured using a single-photon emission computerized tomography technique. In two brain metastases the 57Co-bleomycin concentration measured at different times after the intravenous injection was significantly lower than that in the originating lung tumors (p < 0.01 and p < 0.001). In these two patients, the tumor cumulative concentration (TCC) of drug in the brain neoplasm compared to the lung carcinoma was 12.92 versus 15.12 and 10.30 versus 19.74 μg/cc/min. In the third patient there was no significant difference in drug concentration between the tumor in the brain and in the lung (TCC 16.02 vs. 15.09 μg/cc/min). There was a significant difference in the drug TCC between the three brain metastases: the difference between the lowest and highest concentrations was more than 50% (10.3 vs. 16.02 μg/cc/min). When the concentration in the tumor over time (C(T)(t)) of the 57Co-bleomycin was compared in the brain and lung tumors, a good correlation was found in each of the three cases (r = 0.93, 0.99, and 0.97). This suggests that the difference in drug uptake between brain metastases and their originating lung tumor is a quantitative rather than a qualitative phenomenon. The results show that the amount of drug to which brain metastases are exposed varies and may be very low in some tumors; therefore, effectiveness of drug delivery may play a role in the nonresponsiveness of brain metastases to treatment.

Original languageEnglish
Pages (from-to)506-510
Number of pages5
JournalJournal of Neurosurgery
Volume67
Issue number4
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Dive into the research topics of 'Monitoring of 57Co-bleomycin delivery to brain metastases and their tumors of origin'. Together they form a unique fingerprint.

Cite this